Symbol not found
NASDAQ:SRNE 00:00AM GMT
Products
Sorrento Completes Successfully SAD Study And Initiates MAD Phase 1 Study With STI-1558
Published: 08/03/2022 13:18 GMT
Sorrento Therapeutics Inc (SRNE) - Sorrento Completes Successfully the Sad Study and Initiates the Mad Phase 1 Study With Sti-1558, an Oral M(pro) Inhibitor As a Standalone Treatment and Prevention of Covid-19 Without the Ritonavir As Booster.
Sorrento Therapeutics Inc- Initiation of Multiple Ascending Dose (mad) Portion of Sti-1558 Study Has Been Initiated.
Sorrento Therapeutics Inc- Preliminary Overall Summary of Treatment-emergent Adverse Events Showed That There Were No Serious Aes Or Severe Teaes.
Sorrento Therapeutics Inc- Initiation of Multiple Ascending Dose (mad) Portion of Sti-1558 Study Has Been Initiated.
Sorrento Therapeutics Inc- Preliminary Overall Summary of Treatment-emergent Adverse Events Showed That There Were No Serious Aes Or Severe Teaes.